Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

What Was Tested

The trial (phase 3) is built around Semaglutide.

The trial will be a randomized, double-blind, controlled, single-center trial.

It had two arms (groups): semaglutide group (experimental) and placebo group (placebo comparator).

The patients in the control group will receive a similar-looking Normal Saline.

The registry classes the interventions as drug.

More on the Plan

Endovascular thrombectomy (EVT), a major advance in stroke treatment in recent years, has gained widespread clinical application and become a standard treatment for AIS caused by large-vessel occlusion.

However, in clinical practice, despite successful recanalization of the occluded artery, nearly half of patients do not achieve a favorable prognosis.

The researchers anticipate that this trial will provide valuable insights into the potential role of semaglutide as a neuroprotective agent in patients with ischemic stroke.

Who Took Part

Enrollment: 436 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Clinical or imaging diagnosis of acute ischemic stroke within 24 hours after onset;. Scheduled for endovascular thrombectomy;. Age ≥18 years;. Pre-stroke modified Rankin Scale (mRS) score ≤1;. Informed consent voluntarily signed by the patient or legal representative.

The full record lists 5 inclusion and 8 exclusion criteria; among the exclusions: preoperative imaging diagnosis of intracranial hemorrhage, or history of intracranial hemorrhage within 3 months prior to surgery;; contraindications for endovascular thrombectomy;; recent history of ischemic stroke;.

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

Those kept unaware of assignments: participant and outcomes assessor.

It started in 2025-07-01 with completion listed for 2027-07-31.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: mRS at 90-days (time frame: 90 days postoperatively).

It also tracked 3 secondary outcomes, for example National Institute of Health Stroke Scale (NIHSS) at 24 hours and 7-days, Infarct volume after 72 hours of treatment and the incidence of surgical complications within 90 days postoperatively.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Semaglutide in 436 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.